VA
VYGR icon

Verdad Advisers’s Voyager Therapeutics VYGR Stock Holding History

Verdad Advisers’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
+34,400
New +$130K 0.12% 179

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Verdad Advisers's VYGR Position: Q2 2026 in Review

Verdad Advisers opened a new position in Voyager Therapeutics (VYGR) in Q2 2026: 34,400 shares worth $120K. The stake represents 0.12% of the portfolio and ranks #179 among its holdings.

136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Verdad Advisers held 34,400 shares of Voyager Therapeutics worth $120K as of Q2 2026.
  • Voyager Therapeutics was a new Verdad Advisers position in Q2 2026.
  • Voyager Therapeutics made up 0.12% of Verdad Advisers's portfolio in Q2 2026, its #179 holding.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.